Real-world outcomes of newly diagnosed AML treated with venetoclax and azacitidine or low-dose cytarabine in the UK NHS
-
Published:2024-09
Issue:3
Volume:1
Page:100017
-
ISSN:2950-3280
-
Container-title:Blood Neoplasia
-
language:en
-
Short-container-title:Blood Neoplasia
Author:
Othman JadORCID, Lam Ho Pui JeffORCID, Leong SarahORCID, Basheer Faisal, Abdallah Islam, Fleming Kathryn, Mehta PriyankaORCID, Yassin Heba, Laurie John, Austin MichaelORCID, Gallipoli Paolo, Taylor TomORCID, Dennis Mike, Elliot Johnathon, Clarke Georgina, Dang Raymond, Vidler JenniferORCID, Krishnamurthy Pramila, Latif Anne-Louise, Kalkur Pallavi, Shahidianakbar Maryam, Campbell Victoria, Mannari Deepak, Sutherland Emily, Wickramaratne Thishakya, Collins Angela, Zhao RuiORCID, Mak HerngORCID, Belsham Edward, Banerjee ShabnamORCID, Bashir Jamila, Pillai Srinivas, Whitmill Richard, Galli Sofia, Amer Mariam, Murthy Vidhya, Murray DuncanORCID, Wandroo FarooqORCID, Hogan Francesca, Crolla Francesca, Fowler Nicole, Khan AnjumORCID, O’Nions Jenny, Dillon Richard
Funder
Cancer Research UK
Reference31 articles.
1. Cancer Stat Facts: Leukemia – Acute Myeloid Leukemia (AML),2024 2. Azacitidine and venetoclax in previously untreated acute myeloid leukemia;DiNardo;N Engl J Med,2020 3. Venetoclax plus LDAC for newly diagnosed AML ineligible for intensive chemotherapy: a phase 3 randomized placebo-controlled trial;Wei;Blood,2020 4. Venetoclax duration (14 vs. 21 vs. 28 days) in combination with hypomethylating agent in newly diagnosed acute myeloid leukemia: comparative analysis of response, toxicity, and survival;Karrar;Am J Hematol,2023 5. Duration of cytopenias with concomitant venetoclax and azole antifungals in acute myeloid leukemia;Rausch;Cancer,2021
|
|